The international consortium on lithium genetics (ConLiGen): An initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment

Thomas G. Schulze, Martin Alda, Mazda Adli, Nirmala Akula, Raffaella Ardau, Elise T. Bui, Caterina Chillotti, Sven Cichon, Piotr Czerski, Maria Del Zompo, Sevilla D. Detera-Wadleigh, Paul Grof, Oliver Gruber, Ryota Hashimoto, Joanna Hauser, Rebecca Hoban, Nakao Iwata, Layla Kassem, Tadafumi Kato, Sarah Kittel-SchneiderSebastian Kliwicki, John R. Kelsoe, Ichiro Kusumi, Gonzalo Laje, Susan G. Leckband, Mirko Manchia, Glenda MacQueen, Takuya Masui, Norio Ozaki, Roy H. Perlis, Andrea Pfennig, Paola Piccardi, Sara Richardson, Guy Rouleau, Andreas Reif, Janusz K. Rybakowski, Johanna Sasse, Johannes Schumacher, Giovanni Severino, Jordan W. Smoller, Alessio Squassina, Gustavo Turecki, L. Trevor Young, Takeo Yoshikawa, Michael Bauer, Francis J. McMahon

Research output: Contribution to journalReview article

78 Citations (Scopus)

Abstract

For more than half a decade, lithium has been successfully used to treat bipolar disorder. Worldwide, it is considered the first-line mood stabilizer. Apart from its proven antimanic and prophylactic effects, considerable evidence also suggests an antisuicidal effect in affective disorders. Lithium is also effectively used to augment antidepressant drugs in the treatment of refractory major depressive episodes and prevent relapses in recurrent unipolar depression. In contrast to many psychiatric drugs, lithium has outlasted various pharmacotherapeutic 'fashions', and remains an indispensable element in contemporary psychopharmacology. Nevertheless, data from pharmacogenetic studies of lithium are comparatively sparse, and these studies are generally characterized by small sample sizes and varying definitions of response. Here, we present an international effort to elucidate the genetic underpinnings of lithium response in bipolar disorder. Following an initiative by the International Group for the Study of Lithium-Treated Patients (www.IGSLI.org) and the Unit on the Genetic Basis of Mood and Anxiety Disorders at the National Institute of Mental Health,lithium researchers from around the world have formed the Consortium on Lithium Genetics (www.ConLiGen.org) to establish the largest sample to date for genome-wide studies of lithium response in bipolar disorder, currently comprising more than 1,200 patients characterized for response to lithium treatment. A stringent phenotype definition of response is one of the hallmarks of this collaboration. ConLiGen invites all lithium researchers to join its efforts.

Original languageEnglish
Pages (from-to)72-78
Number of pages7
JournalNeuropsychobiology
Volume62
Issue number1
DOIs
Publication statusPublished - 01-06-2010

Fingerprint

National Institute of Mental Health (U.S.)
Lithium
Therapeutics
Bipolar Disorder
Mood Disorders
Antimanic Agents
Research Personnel
Psychopharmacology
Depressive Disorder
Anxiety Disorders
Sample Size
Antidepressive Agents
Psychiatry

All Science Journal Classification (ASJC) codes

  • Neuropsychology and Physiological Psychology
  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Schulze, Thomas G. ; Alda, Martin ; Adli, Mazda ; Akula, Nirmala ; Ardau, Raffaella ; Bui, Elise T. ; Chillotti, Caterina ; Cichon, Sven ; Czerski, Piotr ; Del Zompo, Maria ; Detera-Wadleigh, Sevilla D. ; Grof, Paul ; Gruber, Oliver ; Hashimoto, Ryota ; Hauser, Joanna ; Hoban, Rebecca ; Iwata, Nakao ; Kassem, Layla ; Kato, Tadafumi ; Kittel-Schneider, Sarah ; Kliwicki, Sebastian ; Kelsoe, John R. ; Kusumi, Ichiro ; Laje, Gonzalo ; Leckband, Susan G. ; Manchia, Mirko ; MacQueen, Glenda ; Masui, Takuya ; Ozaki, Norio ; Perlis, Roy H. ; Pfennig, Andrea ; Piccardi, Paola ; Richardson, Sara ; Rouleau, Guy ; Reif, Andreas ; Rybakowski, Janusz K. ; Sasse, Johanna ; Schumacher, Johannes ; Severino, Giovanni ; Smoller, Jordan W. ; Squassina, Alessio ; Turecki, Gustavo ; Young, L. Trevor ; Yoshikawa, Takeo ; Bauer, Michael ; McMahon, Francis J. / The international consortium on lithium genetics (ConLiGen) : An initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment. In: Neuropsychobiology. 2010 ; Vol. 62, No. 1. pp. 72-78.
@article{7d86b1f359484a5bbb7b15e47f1d1731,
title = "The international consortium on lithium genetics (ConLiGen): An initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment",
abstract = "For more than half a decade, lithium has been successfully used to treat bipolar disorder. Worldwide, it is considered the first-line mood stabilizer. Apart from its proven antimanic and prophylactic effects, considerable evidence also suggests an antisuicidal effect in affective disorders. Lithium is also effectively used to augment antidepressant drugs in the treatment of refractory major depressive episodes and prevent relapses in recurrent unipolar depression. In contrast to many psychiatric drugs, lithium has outlasted various pharmacotherapeutic 'fashions', and remains an indispensable element in contemporary psychopharmacology. Nevertheless, data from pharmacogenetic studies of lithium are comparatively sparse, and these studies are generally characterized by small sample sizes and varying definitions of response. Here, we present an international effort to elucidate the genetic underpinnings of lithium response in bipolar disorder. Following an initiative by the International Group for the Study of Lithium-Treated Patients (www.IGSLI.org) and the Unit on the Genetic Basis of Mood and Anxiety Disorders at the National Institute of Mental Health,lithium researchers from around the world have formed the Consortium on Lithium Genetics (www.ConLiGen.org) to establish the largest sample to date for genome-wide studies of lithium response in bipolar disorder, currently comprising more than 1,200 patients characterized for response to lithium treatment. A stringent phenotype definition of response is one of the hallmarks of this collaboration. ConLiGen invites all lithium researchers to join its efforts.",
author = "Schulze, {Thomas G.} and Martin Alda and Mazda Adli and Nirmala Akula and Raffaella Ardau and Bui, {Elise T.} and Caterina Chillotti and Sven Cichon and Piotr Czerski and {Del Zompo}, Maria and Detera-Wadleigh, {Sevilla D.} and Paul Grof and Oliver Gruber and Ryota Hashimoto and Joanna Hauser and Rebecca Hoban and Nakao Iwata and Layla Kassem and Tadafumi Kato and Sarah Kittel-Schneider and Sebastian Kliwicki and Kelsoe, {John R.} and Ichiro Kusumi and Gonzalo Laje and Leckband, {Susan G.} and Mirko Manchia and Glenda MacQueen and Takuya Masui and Norio Ozaki and Perlis, {Roy H.} and Andrea Pfennig and Paola Piccardi and Sara Richardson and Guy Rouleau and Andreas Reif and Rybakowski, {Janusz K.} and Johanna Sasse and Johannes Schumacher and Giovanni Severino and Smoller, {Jordan W.} and Alessio Squassina and Gustavo Turecki and Young, {L. Trevor} and Takeo Yoshikawa and Michael Bauer and McMahon, {Francis J.}",
year = "2010",
month = "6",
day = "1",
doi = "10.1159/000314708",
language = "English",
volume = "62",
pages = "72--78",
journal = "Neuropsychobiology",
issn = "0302-282X",
publisher = "S. Karger AG",
number = "1",

}

Schulze, TG, Alda, M, Adli, M, Akula, N, Ardau, R, Bui, ET, Chillotti, C, Cichon, S, Czerski, P, Del Zompo, M, Detera-Wadleigh, SD, Grof, P, Gruber, O, Hashimoto, R, Hauser, J, Hoban, R, Iwata, N, Kassem, L, Kato, T, Kittel-Schneider, S, Kliwicki, S, Kelsoe, JR, Kusumi, I, Laje, G, Leckband, SG, Manchia, M, MacQueen, G, Masui, T, Ozaki, N, Perlis, RH, Pfennig, A, Piccardi, P, Richardson, S, Rouleau, G, Reif, A, Rybakowski, JK, Sasse, J, Schumacher, J, Severino, G, Smoller, JW, Squassina, A, Turecki, G, Young, LT, Yoshikawa, T, Bauer, M & McMahon, FJ 2010, 'The international consortium on lithium genetics (ConLiGen): An initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment', Neuropsychobiology, vol. 62, no. 1, pp. 72-78. https://doi.org/10.1159/000314708

The international consortium on lithium genetics (ConLiGen) : An initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment. / Schulze, Thomas G.; Alda, Martin; Adli, Mazda; Akula, Nirmala; Ardau, Raffaella; Bui, Elise T.; Chillotti, Caterina; Cichon, Sven; Czerski, Piotr; Del Zompo, Maria; Detera-Wadleigh, Sevilla D.; Grof, Paul; Gruber, Oliver; Hashimoto, Ryota; Hauser, Joanna; Hoban, Rebecca; Iwata, Nakao; Kassem, Layla; Kato, Tadafumi; Kittel-Schneider, Sarah; Kliwicki, Sebastian; Kelsoe, John R.; Kusumi, Ichiro; Laje, Gonzalo; Leckband, Susan G.; Manchia, Mirko; MacQueen, Glenda; Masui, Takuya; Ozaki, Norio; Perlis, Roy H.; Pfennig, Andrea; Piccardi, Paola; Richardson, Sara; Rouleau, Guy; Reif, Andreas; Rybakowski, Janusz K.; Sasse, Johanna; Schumacher, Johannes; Severino, Giovanni; Smoller, Jordan W.; Squassina, Alessio; Turecki, Gustavo; Young, L. Trevor; Yoshikawa, Takeo; Bauer, Michael; McMahon, Francis J.

In: Neuropsychobiology, Vol. 62, No. 1, 01.06.2010, p. 72-78.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The international consortium on lithium genetics (ConLiGen)

T2 - An initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment

AU - Schulze, Thomas G.

AU - Alda, Martin

AU - Adli, Mazda

AU - Akula, Nirmala

AU - Ardau, Raffaella

AU - Bui, Elise T.

AU - Chillotti, Caterina

AU - Cichon, Sven

AU - Czerski, Piotr

AU - Del Zompo, Maria

AU - Detera-Wadleigh, Sevilla D.

AU - Grof, Paul

AU - Gruber, Oliver

AU - Hashimoto, Ryota

AU - Hauser, Joanna

AU - Hoban, Rebecca

AU - Iwata, Nakao

AU - Kassem, Layla

AU - Kato, Tadafumi

AU - Kittel-Schneider, Sarah

AU - Kliwicki, Sebastian

AU - Kelsoe, John R.

AU - Kusumi, Ichiro

AU - Laje, Gonzalo

AU - Leckband, Susan G.

AU - Manchia, Mirko

AU - MacQueen, Glenda

AU - Masui, Takuya

AU - Ozaki, Norio

AU - Perlis, Roy H.

AU - Pfennig, Andrea

AU - Piccardi, Paola

AU - Richardson, Sara

AU - Rouleau, Guy

AU - Reif, Andreas

AU - Rybakowski, Janusz K.

AU - Sasse, Johanna

AU - Schumacher, Johannes

AU - Severino, Giovanni

AU - Smoller, Jordan W.

AU - Squassina, Alessio

AU - Turecki, Gustavo

AU - Young, L. Trevor

AU - Yoshikawa, Takeo

AU - Bauer, Michael

AU - McMahon, Francis J.

PY - 2010/6/1

Y1 - 2010/6/1

N2 - For more than half a decade, lithium has been successfully used to treat bipolar disorder. Worldwide, it is considered the first-line mood stabilizer. Apart from its proven antimanic and prophylactic effects, considerable evidence also suggests an antisuicidal effect in affective disorders. Lithium is also effectively used to augment antidepressant drugs in the treatment of refractory major depressive episodes and prevent relapses in recurrent unipolar depression. In contrast to many psychiatric drugs, lithium has outlasted various pharmacotherapeutic 'fashions', and remains an indispensable element in contemporary psychopharmacology. Nevertheless, data from pharmacogenetic studies of lithium are comparatively sparse, and these studies are generally characterized by small sample sizes and varying definitions of response. Here, we present an international effort to elucidate the genetic underpinnings of lithium response in bipolar disorder. Following an initiative by the International Group for the Study of Lithium-Treated Patients (www.IGSLI.org) and the Unit on the Genetic Basis of Mood and Anxiety Disorders at the National Institute of Mental Health,lithium researchers from around the world have formed the Consortium on Lithium Genetics (www.ConLiGen.org) to establish the largest sample to date for genome-wide studies of lithium response in bipolar disorder, currently comprising more than 1,200 patients characterized for response to lithium treatment. A stringent phenotype definition of response is one of the hallmarks of this collaboration. ConLiGen invites all lithium researchers to join its efforts.

AB - For more than half a decade, lithium has been successfully used to treat bipolar disorder. Worldwide, it is considered the first-line mood stabilizer. Apart from its proven antimanic and prophylactic effects, considerable evidence also suggests an antisuicidal effect in affective disorders. Lithium is also effectively used to augment antidepressant drugs in the treatment of refractory major depressive episodes and prevent relapses in recurrent unipolar depression. In contrast to many psychiatric drugs, lithium has outlasted various pharmacotherapeutic 'fashions', and remains an indispensable element in contemporary psychopharmacology. Nevertheless, data from pharmacogenetic studies of lithium are comparatively sparse, and these studies are generally characterized by small sample sizes and varying definitions of response. Here, we present an international effort to elucidate the genetic underpinnings of lithium response in bipolar disorder. Following an initiative by the International Group for the Study of Lithium-Treated Patients (www.IGSLI.org) and the Unit on the Genetic Basis of Mood and Anxiety Disorders at the National Institute of Mental Health,lithium researchers from around the world have formed the Consortium on Lithium Genetics (www.ConLiGen.org) to establish the largest sample to date for genome-wide studies of lithium response in bipolar disorder, currently comprising more than 1,200 patients characterized for response to lithium treatment. A stringent phenotype definition of response is one of the hallmarks of this collaboration. ConLiGen invites all lithium researchers to join its efforts.

UR - http://www.scopus.com/inward/record.url?scp=77951941717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951941717&partnerID=8YFLogxK

U2 - 10.1159/000314708

DO - 10.1159/000314708

M3 - Review article

C2 - 20453537

AN - SCOPUS:77951941717

VL - 62

SP - 72

EP - 78

JO - Neuropsychobiology

JF - Neuropsychobiology

SN - 0302-282X

IS - 1

ER -